Lead poisoning. Poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics, undetermined intent
Conditions
Interventions
Intervention 1: Control group: Receiving standard treatment for lead poisoning. Because one of the inclusion criteria is that patients do not need to be treated with chelators, the standard treatment
Sponsors
Toxicological Research Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Serum Lead level between 20 and 60 µg/dL. Not having severe clinical symptoms of Lead poisoning and as a result no need to prescribe standard chelators. Patients who had informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: Allergic reaction to zeolite compounds. Previous receipt of chelator drugs that are routinely prescribed in the standard treatment of Lead poisoning. Patients with any kinds of underlying disease including hepatic disorder, diabetes, heart failure, renal failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Normal serum level of Lead. Timepoint: The serum levels of Lead will be measured before the administration of Zeolive and 14 days after the start of its administration. Method of measurement: Serum levels of Lead will be measured using the COBAS-INTEGRA 400 Plus. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count (CBC). Timepoint: Complete blood count (CBC) will be counted at the beginning of the study (before Zeolive administration) and 14 days after its administration. Method of measurement: Complete blood count will be measured using the Sysmex-KX-21.;Serum electrolyte measurement. Timepoint: Serum electrolytes will be measured at the beginning of the study (before Zeolive administration) and 14 days after its administration. Method of measurement: Serum electrolyte measurement will be done using Medica-EasyLyte.;Measurement of Creatinine and Blood Urea Nitrogen levels. Timepoint: Creatinine and Blood Urea Nitrogen levels will be measured at the beginning of the study (before Zeolive administration) and 14 days after its administration. Method of measurement: Creatinine and Blood Urea Nitrogen levels will be measured using the Mindray BS-800. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahin Shadnia
Shahid Beheshti University of Medical Sciences
Outcome results
None listed